Frazier Lifesciences Acquisition Corporation Stock
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.9 EUR | -6.87% | +2.51% | +72.07% |
Sales 2024 * | 8.6M 9.26M | Sales 2025 * | 6.3M 6.77M | Capitalization | 1.61B 1.73B |
---|---|---|---|---|---|
Net income 2024 * | -209M -225M | Net income 2025 * | -139M -150M | EV / Sales 2024 * | 187 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 255 x |
P/E ratio 2024 * |
-7.66
x | P/E ratio 2025 * |
-11.9
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Frazier Lifesciences Acquisition Corporation
1 day | -6.87% | ||
1 week | +2.51% | ||
Current month | +2.51% | ||
1 month | -12.08% | ||
3 months | -8.35% | ||
6 months | +96.12% | ||
Current year | +72.07% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 19.22 | +1.91% | 51 759 |
24-06-07 | 19.3 | -1.53% | 56,948 |
24-06-06 | 19.6 | +1.98% | 175,779 |
24-06-05 | 19.22 | +1.91% | 51,759 |
24-06-04 | 18.86 | -0.32% | 86,760 |
End-of-day quote Nasdaq, June 04, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.07% | 1.74B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.42% | 22.78B | |
-10.46% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- NAMS Stock